Published in Clin J Pain on October 23, 2006
Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage (2009) 1.96
What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. Drugs (2016) 1.50
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol (2009) 0.93
A comprehensive review of rapid-onset opioids for breakthrough pain. CNS Drugs (2012) 0.93
Considerations in selecting rapid-onset opioids for the management of breakthrough pain. J Pain Res (2013) 0.92
Characterization of cancer-induced bone pain: an exploratory study. Support Care Cancer (2010) 0.85
Fentanyl transmucosal tablets: current status in the management of cancer-related breakthrough pain. Patient Prefer Adherence (2012) 0.84
Intranasal fentanyl for pain control: current status with a focus on patient considerations. Patient Prefer Adherence (2011) 0.83
Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. Adv Ther (2014) 0.80
Emerging drugs for cancer-related pain. Support Care Cancer (2011) 0.79
Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. Perspect Medicin Chem (2010) 0.78
The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Support Care Cancer (2010) 0.78
Canadian recommendations for the management of breakthrough cancer pain. Curr Oncol (2016) 0.77
Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med (2012) 0.77
Pharmacologic management of adult breakthrough cancer pain. Can Fam Physician (2014) 0.76
Single-dose fentanyl sublingual spray for breakthrough cancer pain. Clin Pharmacol (2013) 0.75
Extent of Fentanyl Accumulation Following Multiple Doses of Fentanyl Buccal Tablet 400 microg in Healthy Japanese Volunteers. Arch Drug Inf (2008) 0.75
A new transmucosal drug delivery system for patients with breakthrough cancer pain: the fentanyl effervescent buccal tablet. J Pain Res (2008) 0.75
Relative Bioavailability of Fentanyl Following Various Dosing Regimens of Fentanyl Buccal Tablet in Healthy Japanese Volunteers. Arch Drug Inf (2008) 0.75
Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Support Care Cancer (2015) 0.75
Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. J Pain Symptom Manage (2017) 0.75
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2009) 2.68
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood (2011) 2.66
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol (2007) 1.18
Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain (2006) 1.16
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk (2010) 1.13
Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study. Cancer (2009) 1.11
A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Contemp Clin Trials (2012) 1.03
Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin (2007) 0.94
The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg (2011) 0.91
Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain. Support Care Cancer (2011) 0.90
Comorbid illness affects hospital costs related to hip arthroplasty: quantification of health status and implications for fair reimbursement and surgeon comparisons. J Arthroplasty (2004) 0.89
Partial Pyridoxine Responsiveness in PNPO Deficiency. JIMD Rep (2012) 0.89
Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther (2007) 0.86
Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening. Prim Care Companion J Clin Psychiatry (2000) 0.85
Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin Neuropharmacol (2002) 0.85
Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder. Headache (2013) 0.83
Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage (2010) 0.83
All-human microphysical model of metastasis therapy. Stem Cell Res Ther (2013) 0.83
A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study). Headache (2014) 0.82
Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract (2010) 0.80
Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. Perspect Medicin Chem (2010) 0.78
Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag (2011) 0.77
Breakthrough pain in opioid-treated patients with neuropathic pain. J Opioid Manag (2007) 0.76
Clinical pharmacology of fentanyl buccal tablet for the treatment of breakthrough pain. Expert Rev Clin Pharmacol (2008) 0.75
Assessment of the relative potency of fentanyl buccal tablet to intravenous morphine in healthy volunteers using a thermally induced hyperalgesia pain model. J Clin Pharmacol (2011) 0.75